Please login to the form below

Not currently logged in
Email:
Password:

Allergy Therapeutics

This page shows the latest Allergy Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: UK must follow through on Life Sciences Strategy, haemophilia gene therapy latest and more

Daily Brief: UK must follow through on Life Sciences Strategy, haemophilia gene therapy latest and more

Meanwhile UK biotech company Allergy Therapeutics has some good news at last from its long-delayed allergy treatment.

Latest news

  • Positive mid-stage trial gives Allergy’s investors some welcome relief Positive mid-stage trial gives Allergy’s investors some welcome relief

    Allergy Therapeutics’long-stalled efforts to develop a grass pollen allergy candidate finally seem to have lurched into motion, with a positive phase II trial setting up registration trials next year. ... This study represents a major milestone in our

  • Nestlé Health Science invests $145m in food allergy biotech Nestlé Health Science invests $145m in food allergy biotech

    Nestlé Health Science invests $145m in food allergy biotech. Aimmune Therapeutics' lead product is a phase III peanut allergy treatment. ... An oral biologic containing the protein profile found in peanuts, AR101 is designed to desensitise patients with

  • Consilium wins Allergy Therapeutics account Consilium wins Allergy Therapeutics account

    Consilium wins Allergy Therapeutics account. Will advise the firm on international investor relations. ... Consilium Strategic Communications has been appointed by specialty pharmaceutical firm Allergy Therapeutics as its international investor relations

  • Leaning forward

    Leaning forward. Allergy Therapeutics used lean management tools to make their Odyssey of improvement. ... Allergy Therapeutics develops, manufactures and sells a range of pharmaceutical products for the treatment and prevention of allergy.

  • Yo-yoing

    Shares in Allergy Therapeutics, a specialist pharmaceutical company that focuses on allergy vaccination, benefited from news that it has achieved a positive outcome for its key clinical efficacy and safety study ... R204, which marks an important step in

More from news
Approximately 2 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • Deal Watch table for August 2014 Deal Watch table for August 2014

    587.5. Santaris/ Roche (pRED). Company acquisition. Locked Nucleic Acid (LNA) platform for RNA-targeting therapeutics. ... 183. Immune Design/ Sanofi. Licence. GLAAS discovery platform to develop therapeutics for a selected food allergy.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Hanson Zandi

    Allergy Therapeutics - Allergy products. CSL Behring - Corporate, Critical care, Immunology.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics